Financial News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
July 26, 2024 at 08:42 AM EDT
The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
